TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06005402

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CSX-1004
Description: Recombinant human immunoglobulin G (IgG) 1λ monoclonal antibody specific for fentanyl and structurally related fentanyl analogs

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Sterile saline for injection
Study: NCT06479356

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Relma-cel
Description: Relma-cel will be administered at one dose level:1×10\^8 CAR+T cells
Study: NCT05521932

Intervention type: OTHER
Intervention: endometrium collected
Description: endometrium tissue collected following adhesiolysis surgery
Study: NCT05036343

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: InPen®
Description: A smartpen that has been FDA approved for children with diabetes age seven years and older that uses an app on a smartphone to help calculate insulin doses using the amount of carbohydrates that will be consumed at a meal along with what the current blood sugar reading is, to give a correction dose as well. The InPen app also serves as a log book to record insulin doses given, blood sugar at the time of a meal, and amount of carbohydrate eaten.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: InPen®
Description: A smartpen that has been FDA approved for children with diabetes age seven years and older that uses an app on a smartphone to help calculate insulin doses using the amount of carbohydrates that will be consumed at a meal along with what the current blood sugar reading is, to give a correction dose as well. The InPen app also serves as a log book to record insulin doses given, blood sugar at the time of a meal, and amount of carbohydrate eaten.
Study: NCT05990686

Intervention type: DRUG
Intervention: Tramadol Hydrochloride
Description: After routine pre-operative evaluation, standard monitors will be connected to the patients: pulse oximetery, noninvasive blood pressure and electrocardiogram and baseline parameter will be recorded (heart rate, mean arterial pressure and peripheral oxygen saturation). Intravenous (IV) line will be inserted for all patients, and IV fluid will be started.~Intravenous infusion of 15mg/kg paracetamol together with 1mg/kg tramadol will be started and to be finished before starting of induction of anaesthesia (induction agent will be Propofol 2mg/kg)

Intervention type: DRUG
Intervention: Fentanyl injection
Description: After routine pre-operative evaluation, standard monitors will be connected to the patients: pulse oximetery, noninvasive blood pressure and electrocardiogram and baseline parameter will be recorded (heart rate, mean arterial pressure and peripheral oxygen saturation). Intravenous (IV) line will be inserted for all patients, and IV fluid will be started...Intravenous injection of 1microgram/kg fentanyl will be given to the patient followed by induction agents ( propofol 2mg/kg).~.
Study: NCT06408376

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Physiological cord clamping
Description: Immediately after birth, the newborn with prenatal diagnosis of CDH will be placed on a mobile table, made to receive these patients in the delivery room, at the level of the mother's womb, leaving the umbilical cord intact and intubated. The patient will be gently ventilated (PIM 15/25 - PEEP 4 - Fio2 50%), until saturation \>85% and HR\>100 or 10 timed minutes have elapsed, whichever occurs first, the umbilical cord will be clamped.
Study: NCT05325684

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PD-L1 inhibitor
Description: Enrolled patients received durvalumab/ Atezolizumab plus chemotherapy or target therapy treatment (durvalumab,1000mg，iv, d1, 21day as a cycle; Atezolizumab,1200mg iv, d1, 21day as a cycle.)
Study: NCT05363592

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CT-L01 12.5/500 mg
Description: FDC tablet, 2 tablets at a time, oral administration

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Alogliptin Benzoate 12.5 mg
Description: Alogliptin Benzoate 12.5 mg 2 tablets, at a time, oral administration

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metformin HCl XR 500 mg
Description: Metformin HCl XR 500 mg 2 tablets, at a time, oral administration
Study: NCT05508438

Intervention type: DEVICE
Group type: OTHER
Intervention: Transfemoral mitral-valve repair
Description: Transfemoral mitral-valve repair
Study: NCT06101810

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: COMET
Description: information already included in arm/group descriptions.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CBT
Description: information already included in arm/group descriptions.
Study: NCT05636839

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: UVB treatment
Description: UVB treatment 3 times per week for 10 weeks
Study: NCT05164471

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: verbrinacogene setparvovec
Description: FLT180a is a gene therapy intended to increase endogenous FIX production in adults with Hemophilia B
Study: NCT05210725

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rivaroxaban 2.5 Mg Oral Tablet
Description: 2.5 mg rivaroxaban twice a day in addition to acetylsalicylic acid (80-00mg once a day, standard care).
Study: NCT05249088

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Protocolised reduction of non-resuscitation fluids
Description: * Maintenance fluids are discontinued in participants with positive cumulative fluid balance who are not dehydrated~* Intravenous fluid and enteral water are given as needed to correct electrolyte disturbances~* Enteral nutrition with energy density of at least 2 kcal/ml is administered according to local practice~* Starting 72 hours after inclusion, glucose at a concentration of at least 20% and a maximal dose of 1g/kg/day may be used as nutrition if enteral feeding is not tolerated. Glucose at this dose or lower may be started earlier in patients with insulin dependent diabetes if enteral feeding is not tolerated and local protocol mandates this~* Parenteral nutrition is administered according to local protocol~* Intravenous medications are concentrated according to a predefined protocol~* Patients with neutral or negative cumulative fluid balance receive maintenance and other fluids such that total dose of fluids covers the daily need of water (about 1ml/kg/h)
Study: NCT04747288

Intervention type: DIAGNOSTIC_TEST
Intervention: Schirmer's test
Description: Autoimmune disease (AID) as Sjögren's syndrome (SJS) and Systemic lupus erythematosus (SLE) for comparing with the Dry eye syndrome (DES) subjects will take the Schirmer's test.

Intervention type: DIAGNOSTIC_TEST
Intervention: Schirmer's test
Description: Autoimmune disease (AID) as Sjögren's syndrome (SJS) and Systemic lupus erythematosus (SLE) for comparing with the Dry eye syndrome (DES) subjects will take the Schirmer's test.

Intervention type: DIAGNOSTIC_TEST
Intervention: Schirmer's test
Description: Autoimmune disease (AID) as Sjögren's syndrome (SJS) and Systemic lupus erythematosus (SLE) for comparing with the Dry eye syndrome (DES) subjects will take the Schirmer's test.

Intervention type: DIAGNOSTIC_TEST
Intervention: Ocular Surface Diseast Index (OSDI)
Description: Autoimmune disease (AID) as Sjögren's syndrome (SJS) and Systemic lupus erythematosus (SLE) for comparing with the Dry eye syndrome (DES) subjects will take the Ocular Surface Diseast Index (OSDI).
Study: NCT05249088

Intervention type: OTHER
Group type: OTHER
Intervention: Usual care
Description: Participants receive non-resuscitation fluids according to local routines, with the following stipulations:~* Maintenance fluids (crystalloids and/or glucose and/or enteral water) are given at a dose of 1 ml/kg/h unless local protocol states otherwise~* Glucose is used at maximal concentration of 10% unless local protocol states otherwise.~* Medications are concentrated according to local protocol
Study: NCT04995328

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Radiation Care Gel
Description: The investigational medical product of this study is a hydrogel, Radiation Care® gel which increases moisturizing and it can be applied to the target areas including skin folds and creases.
Study: NCT05212155

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: family-based behavioral treatment (FBT)
Description: Individual and group treatment of parent/child dyads to improve dietary choices, minimize sedentary behaviors, increase physical activity levels, and identify social support environments that reinforce healthy lifestyle choices.
Study: NCT05649618

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Tumor Infiltrating Lymphocytes
Description: On day 0 patients will be intravenous infusion of TILs

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Part of the non-myeloablative lymphocyte-depleting preparative regimen

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide Capsules
Description: Part of the non-myeloablative lymphocyte-depleting preparative regimen.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IL-2
Description: Following cell infusion, the patient receives high-dose bolus IL-2, which is dosed to individual patient tolerance.
Study: NCT05785390

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NP-101
Description: NP-101 is an organically derived, GMP manufactured product covered under IND #152687.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Identical placebo
Study: NCT04747288

Intervention type: DIAGNOSTIC_TEST
Intervention: Ocular Surface Diseast Index (OSDI)
Description: Autoimmune disease (AID) as Sjögren's syndrome (SJS) and Systemic lupus erythematosus (SLE) for comparing with the Dry eye syndrome (DES) subjects will take the Ocular Surface Diseast Index (OSDI).

Intervention type: DIAGNOSTIC_TEST
Intervention: Ocular Surface Diseast Index (OSDI)
Description: Autoimmune disease (AID) as Sjögren's syndrome (SJS) and Systemic lupus erythematosus (SLE) for comparing with the Dry eye syndrome (DES) subjects will take the Ocular Surface Diseast Index (OSDI).

Intervention type: DIAGNOSTIC_TEST
Intervention: EULAR Sjögren's Syndrome Patient Reported Index (ESSPRI)
Description: Autoimmune disease (AID) as Sjögren's syndrome (SJS) and Systemic lupus erythematosus (SLE) for comparing with the Dry eye syndrome (DES) subjects will take the EULAR Sjögren's Syndrome Patient Reported Index (ESSPRI).

Intervention type: DIAGNOSTIC_TEST
Intervention: EULAR Sjögren's Syndrome Patient Reported Index (ESSPRI)
Description: Autoimmune disease (AID) as Sjögren's syndrome (SJS) and Systemic lupus erythematosus (SLE) for comparing with the Dry eye syndrome (DES) subjects will take the EULAR Sjögren's Syndrome Patient Reported Index (ESSPRI).

Intervention type: DIAGNOSTIC_TEST
Intervention: EULAR Sjögren's Syndrome Patient Reported Index (ESSPRI)
Description: Autoimmune disease (AID) as Sjögren's syndrome (SJS) and Systemic lupus erythematosus (SLE) for comparing with the Dry eye syndrome (DES) subjects will take the EULAR Sjögren's Syndrome Patient Reported Index (ESSPRI).

Intervention type: DIAGNOSTIC_TEST
Intervention: 36-Item Short Form Survey (SF-36)
Description: Autoimmune disease (AID) as Sjögren's syndrome (SJS) and Systemic lupus erythematosus (SLE) for comparing with the Dry eye syndrome (DES) subjects will take the 36-Item Short Form Survey (SF-36).

Intervention type: DIAGNOSTIC_TEST
Intervention: 36-Item Short Form Survey (SF-36)
Description: Autoimmune disease (AID) as Sjögren's syndrome (SJS) and Systemic lupus erythematosus (SLE) for comparing with the Dry eye syndrome (DES) subjects will take the 36-Item Short Form Survey (SF-36).

Intervention type: DIAGNOSTIC_TEST
Intervention: 36-Item Short Form Survey (SF-36)
Description: Autoimmune disease (AID) as Sjögren's syndrome (SJS) and Systemic lupus erythematosus (SLE) for comparing with the Dry eye syndrome (DES) subjects will take the 36-Item Short Form Survey (SF-36).
Study: NCT05732246

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: First rib mobilization with balloon breathing exercises
Description: Patient was in the supine position, placing the soles of his feet against the wall so that the ankle, knee, and thigh joints are at a 90-degree angle. The subject placed a 3-4-inch ball between his/her knees, which he/she has to maintain through the pressure of the internal thigh muscles during the whole training period and puts his/her back on the bed. Holds the right hand above the head and the left hand with the balloon. Meanwhile examiner would palpate 1st rib with head in left side flexion. Patient was then asked to inhale through the nose in three-four seconds and then exhales slowly into the balloon. Then, holding the first rib in place, the patient was asked to inhale and exhale deeply again. The examiner continued applying pressure to hold the first rib in a position of relative depression during inhalation, and further depressed the first rib as able during exhalation.
Study: NCT05054764

Intervention type: DEVICE
Intervention: Promus PREMIER BTK DES
Description: Collect one year data of the Promus PREMIER BTK drug eluting stent in CLTI patients
Study: NCT05755334

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ropivacaine
Description: Administration of Ropivacaine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ropivacaine
Description: Administration of Ropivacaine
Study: NCT05242640

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mindful attention
Description: Participants will listen to mindful attention audio recordings via headphones

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise
Description: Participants will complete a moderate-intensity walking program

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise with mindful attention
Description: Participants will complete a moderate-intensity walking program while listening to mindful attention audio recordings via headphones
Study: NCT06223568

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: Docetaxel 75 mg/m\^2 will be administered over 60 (+/-10) minutes.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: Docetaxel 75 mg/m\^2 will be administered over 60 (+/-10) minutes.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Cisplatin 75 mg/m\^2 will be administered over 120 (+/-10) minutes.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Cisplatin 75 mg/m\^2 will be administered over 120 (+/-10) minutes.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PRGN-2009
Description: PRGN-2009 will be administered in Arm 2 participants only as an SQ injection in the arm at a dose of 1 mL nominally containing 5x10\^11 viral particles (VP) on Day -7 (+/-3 days) of Cycle 1, Day 11 (+/-3 days) of Cycles 1, 2, and 3.
Study: NCT06562608

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anticholinergic Deprescription
Description: per routine clinical care, people in the active arm of the study will undergo deprescription of benztropine or trihexyphenidyl per routine clinical care.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: No Anticholinergic Deprescription
Description: In this arm, no deprescription of benztropine or trihexyphenidyl will occur.
Study: NCT06051604

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Mi-Helper
Description: The Mi-Helper device is a non-invasive, drug-free, novel therapy that uses a patented process of dry air flow across the nasal turbinates to induce a phase change (evaporation) that extracts energy (thermodynamics) causing local cooling which modulates nerves associated with pain and other symptoms of migraine. The device delivers a controlled pressure and flow of dry room temperature air along with a nebulized saline mist for added comfort and evaporative efficiency.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Mi-Helper
Description: The Mi-Helper device is a non-invasive, drug-free, novel therapy that uses a patented process of dry air flow across the nasal turbinates to induce a phase change (evaporation) that extracts energy (thermodynamics) causing local cooling which modulates nerves associated with pain and other symptoms of migraine. The device delivers a controlled pressure and flow of dry room temperature air along with a nebulized saline mist for added comfort and evaporative efficiency.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Mi-Helper
Description: The Mi-Helper device is a non-invasive, drug-free, novel therapy that uses a patented process of dry air flow across the nasal turbinates to induce a phase change (evaporation) that extracts energy (thermodynamics) causing local cooling which modulates nerves associated with pain and other symptoms of migraine. The device delivers a controlled pressure and flow of dry room temperature air along with a nebulized saline mist for added comfort and evaporative efficiency.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Mi-Helper
Description: The Mi-Helper device is a non-invasive, drug-free, novel therapy that uses a patented process of dry air flow across the nasal turbinates to induce a phase change (evaporation) that extracts energy (thermodynamics) causing local cooling which modulates nerves associated with pain and other symptoms of migraine. The device delivers a controlled pressure and flow of dry room temperature air along with a nebulized saline mist for added comfort and evaporative efficiency.
Study: NCT05591898

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Progressive relaxation exercises
Description: Training booklet and CD as a guide on the implementation of Progressive Relaxation Exercises prepared by the Turkish Psychological Association; muscle relaxation exercises, rhythmic breathing and music recital. In the first 10 minutes of this three-part CD, the definition and purpose of deep relaxation and the practices to be considered during exercise are explained. In the second part of 30 minutes; relaxation exercises are explained with the sound of the stream and verbal instructions. The third part, consisting of 30 minutes; it contains only relaxation music without instructions.
Study: NCT06375291

Intervention type: OTHER
Intervention: splint /steroid injection/both
Description: pregnant women treated in pain department by splint /steroid injection/both

Intervention type: OTHER
Intervention: splint /steroid injection/both
Description: pregnant women treated in pain department by splint /steroid injection/both
Study: NCT05669807

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Camrelizumab
Description: 200mg d1, the first day, every 14 days as a cycle
Study: NCT05329220

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ABNCoV2
Description: ABNCoV2 100μg single dose

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Comirnaty
Description: Comirnaty
Study: NCT06375291

Intervention type: OTHER
Intervention: splint /steroid injection/both
Description: pregnant women treated in pain department by splint /steroid injection/both
Study: NCT05939063

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: LRAMPS
Description: For LRAMPS procedure, Gerota's fascia and perirenal fat capsule are removed, and the procedure is divided into anterior LRAMPS and posterior LRAMPS depending on whether the left adrenal gland is resected. The N1 station lymph nodes (i.e., groups 10, 11, and 18) in the body and tail of the pancreas are removed. If the tumor is located near the pancreatic body, the No. 9 lymph node group is additionally removed.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: LDP
Description: For LDP procedure, the dissection plane is located behind the fusion fascia. The N1 station lymph nodes (i.e., groups 10, 11, and 18) in the body and tail of the pancreas are removed. If the tumor is located near the pancreatic body, the No. 9 lymph node group is additionally removed.
Study: NCT05669807

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Camrelizumab
Description: 200mg d1, the first day, every 14 days as a cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Albumin-Bound Paclitaxel
Description: 100 mg/m2, the 1st, 8th and 15th days, every 28 days as a cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan
Description: 180 mg/m2, the first day, every 14 days as a cycle
Study: NCT05693818

Intervention type: OTHER
Intervention: Clinical Limping Evalution
Description: Patients will be asked to perform a Clinical Limping Evaluation in the clinic during their post-operative follow-up visit. This will be performed in a controlled environment within the physician's clinic. Each patient will be asked to walk at their normal walking speed down a hallway for at least 7 consecutive steps and back toward the physician. Walking down the hallway and back is one walking trial. Each patient will be asked to perform 2 walking trials. The health care provider will assess the patient's limp using a 3-point Likert scale (0=No limp, 1=mild/moderate limp, 2=severe limp).~If required, patients may use an assistive device and the type of device should be documented. If a patient requires assistance, only the minimum amount of assistance required for a patient to complete the task should be provided.
Study: NCT04703621

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daratumumab Injection
Description: subcutaneious daratumumab administration
Study: NCT05732259

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Percussion therapy
Description: Participant lying in prone position on the couch will receive percussion therapy with Theragun PRO using standard ball head at speed of 1750 rpm, for total of 90 seconds, split into 3 sets of 30 seconds with 10 seconds rest.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Manual Myofascial Release technique
Description: Manual myofascial release technique for 90 sec continuous.
Study: NCT05420779

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TSL-1502 capsules(low dose)
Description: 350 mg each time, orally administered QD, every 3 weeks as a treatment cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TSL-1502 capsules(high dose)
Description: 500 mg each time, orally administered QD, every 3 weeks as a treatment cycle.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Investigator's choice of chemotherapy
Description: Capecitabine tablets, 1250 mg/m2 each time, BID oral administration; Vinorelbine tartrate injection, 25 \~ 30 mg/m2 each time, intravenous drip (15 \~ 20 min); Eribulin mesylate injection, 1.4 mg/m2 each time, intravenous injection (2 \~ 5 min)
Study: NCT06503107

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nanobody-based biepitope BCMA-targeting CAR-T cells
Description: Each patient will receive nanobody-based biepitope BCMA-targeting CAR-T cell by intravenous infusion on day 0.
Study: NCT04840784

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ETH-155008
Description: ETH-155008 is an orally bioavailable, potent Pim-3 and CDK4/6 dual kinase inhibitor.~Dosage form:10mg, 20 mg and 40 mg, tablets. ETH-155008 tablets should be taken while fasting, either 1 hour before or 2 hours after a meal.